Latest squamous cell carcinoma Stories

With summer over, those who were in the sun without sunscreen are concerned about their skin health. Skin cancer screenings and treatment are offered by Mohs surgeon Dr. Andrew Kaufman as well as other providers at The Center for Dermatology Care. Thousand Oaks, CA (PRWEB) October 23, 2010 Those who spent a lot of time outdoors this summer may be worrying about the health of their skin, according to the Thousand Oaks skin cancer specialists at The Center for Dermatology Care...

In a study to be published online Oct. 21 in PLoS Genetics, researchers at the Stanford University School of Medicine have implicated the lack of a protein important in hooking our skin cells together in the most common variety of skin cancer. Depletion of this protein, called Perp, could be an early indicator of skin cancer development, and could be useful for staging and establishing prognoses.These findings' significance may extend beyond skin cancer, as Perp is found in the linings of...

A survey of patients undergoing skin cancer screening shows that women were more likely to seek screening because of a skin lesion, a family history of skin cancer, or concern about sun exposure, whereas men age 50 and older, a group at highest risk for melanoma, may only seek screenings after a previous skin cancer diagnosis, according to a report in the October issue of Archives of Dermatology, one of the JAMA/Archives journals.In 2008, more than 62,000 Americans were diagnosed with the...

(Ivanhoe Newswire) "“ Non-melanoma skin cancer is the most common cancer in the U.S.. One million people are diagnosed every year. Scientists have discovered that the loss of a gene, INPPF5A, can be used to predict the onset and track the progression of this aggressive skin cancer.Targeting INPPF5A could provide doctors with better ways to treat and even prevent cutaneous squamos cell carcinoma, or SSC. SSC is like an army of invaders that infiltrate the body quickly and tactfully. SSC...

Loss of the gene INPP5A occurs even in earliest stage of SCC diseaseThe loss of a gene known as INPP5A could predict the onset, and track the progression, of an aggressive type of skin cancer, according to a study published today by the Arizona Cancer Center, Mayo Clinic and the Translational Genomics Research Institute (TGen).Targeting INPP5A could provide physicians with better ways to prevent and treat cutaneous squamous cell carcinoma, or SCC, a skin cancer that often spreads to other...

In one of the first studies to focus exclusively on the outcomes after treatment for patients with high-risk prostate cancer,(http://www.mayoclinic.org/prostate-cancer/) researchers have found that surgery provides high survival rates. Collaborating researchers at Mayo Clinic and Fox Chase Cancer Center (http://www.fccc.edu/) in Philadelphia discovered that patients with the most aggressive forms of prostate cancer who had radical prostatectomy procedures had a 10-year cancer-specific...

SUNNYVALE, Calif., Sept. 7 /PRNewswire/ -- BARRX Medical, Inc., a world leader in endoscopic treatment solutions for treating precancerous lesions of the esophagus as well as other chronic gastrointestinal diseases, announced today that the company has signed an exclusive agreement with Medico's Hirata for distribution of the HALO Radiofrequency Ablation System in Japan. Japan has one of the highest concentrations of esophageal squamous cell cancers in the world. Traditionally treated by...

WILMINGTON, Mass., Aug. 6 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.(® )(Nasdaq: DUSA) reported today that on the afternoon of August 5, 2010 the U.S. Food and Drug Administration (FDA) notified DUSA that it has not granted Orphan Drug Designation for the use of Levulan(®) (aminolevulinic acid HCl) Photodynamic Therapy (PDT) for the prevention of cutaneous squamous cell carcinomas (SCCs) in patients who have a proven history of multiple localized cutaneous SCCs over a 12...

BRIDGEWATER, N.J., Aug. 5 /PRNewswire/ -- Sanofi-aventis U.S. announced today that the U.S. Food and Drug Administration (FDA) has approved a new one-vial formulation of its chemotherapeutic agent Taxotere® (docetaxel) Injection Concentrate. The 1-vial Taxotere is anticipated to become available to cancer treatment clinics and hospitals nationwide in the fall in both 80 mg and 20 mg dosages. Introduced more than 14 years ago, Taxotere is approved by the FDA for use in treating patients...

WILMINGTON, Mass., July 29 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc. (Nasdaq: DUSA) announces that its second quarter corporate highlights and financial results press release will be issued on Tuesday, August 3rd at 6:30 a.m. to be followed by a conference call at 8:30 a.m. Tuesday, August 3rd - 8:30 a.m. E.D.T. If calling from North America use the following toll-free number: 800-647-4314...